Menu
Recruiting NCT07411443

AI-Enhanced Imaging in Population Breast Cancer Screening

No phase Interventional Breast Cancer Screening

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AI-assisted screening.
Who it may be relevant to
Registry conditions: Breast Cancer Screening. Basic parameters: 35 years — 69 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Population-based Breast Cancer Screening Study Using AI-Assisted Imaging Technology

Overview

Artificial Intelligence (AI)-assisted imaging technologies (including AI-assisted breast ultrasound and AI-assisted mammography) can effectively improve the accuracy and efficiency of breast imaging examinations, but their application in large-scale population-based breast cancer screening remains very limited. This project aims to improve the effectiveness and feasibility of breast cancer screening by addressing the core issues and bottlenecks in population-based breast cancer screening. We will conduct a prospective cluster-controlled screening trial in the general population, with district-based cluster grouping. The intervention group will undergo combined screening using AI-assisted ultrasound plus AI-assisted mammography, while the control group will receive conventional screening: breast ultrasound for initial screening and mammography for secondary screening. Based on population screening practices, we will evaluate the effectiveness of AI-assisted imaging diagnostic technology in various technical aspects of actual screening and perform cost-effectiveness analyses. This study will investigate the application of AI-assisted breast imaging technology in population-based breast cancer screening, providing scientific evidence for the large-scale implementation of AI-assisted imaging technologies. Furthermore, by combining population screening practices with model simulations, we will explore multi-dimensional breast cancer screening strategies to optimize screening approaches and technologies for the Chinese population.

Interventions

  • Device AI-assisted screening
    The intervention group will undergo combined screening using AI-assisted ultrasound plus AI-assisted mammography

Primary outcome measures

  • The incidence of early-stage breast cancer over a one-year follow-up period, compared between women who underwent AI-assisted screening and those with routine screening [Time frame: From enrollment to 1-year after the end of screening]
  • The detection rate of suspicious breast lesions (including masses and calcifications) over a one-year follow-up period, compared between women who underwent AI-assisted ultrasound combined with AI-assisted mammography and those who received routine scree [Time frame: From enrollment to 1-year after the end of screening]

Eligibility criteria

Inclusion criteria

  • women aged 35 to 69 years, who were attending the "Two Cancers (Breast and Cervical Cancer) Screening" project, and had no history of breast cancer, including in-situ cancer, or any other cancers in the previous five years.

Exclusion criteria

  • have serious cardiopulmonary insufficiency, liver or kidney insufficiency, or other systemic diseases, and a life expectancy of less than five years

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Screening

Study locations

China · 1 center
  • Fudan University Shanghai Cancer Center — Shanghai

Identifiers

NCT: NCT07411443 · 2024AI

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗